CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds
S. Amarilla-Quintana, P. Navarro, A. Ramos, A. Montero-Calle, P. Cabezas-Sainz, M. J. Barrero, D. Megias, B. Vilaplana-Marti, C. Epifano, D. Gomez-Dominguez, I. Hernandez, S. Monzon, I. Cuesta, L. Sanchez, R. Barderas, , I. Perez de Castro
This study uses CRISPR to eliminate the FOXL2 c.402C>G mutation in granulosa tumor cells, reducing malignancy and identifying anti-tumoral compounds.
Molecular Oncology · Jan 8, 2025Peer-reviewedCancer Biology